US Patent

US8420663 — Peripheral opioid receptor antagonists and uses thereof

Method of Use · Assigned to Wyeth LLC · Expires 2029-09-30 · 3y remaining

Vulnerability score 73/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a compound of formula I and compositions thereof, assigned to Wyeth LLC.

USPTO Abstract

The present invention provides a compound of formula I: wherein X â , R 1 , and R 2 are as defined herein, and compositions thereof.

Drugs covered by this patent

methylnaltrexone-bromide (METHYLNALTREXONE BROMIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1185`	—	methylnaltrexone-bromide
`U-1185`	—	methylnaltrexone-bromide
`U-1185`	—	methylnaltrexone-bromide
`U-1185`	—	methylnaltrexone-bromide

Patent Metadata

Patent number: US8420663
Jurisdiction: US
Classification: Method of Use
Expires: 2029-09-30
Drug substance claim: No
Drug product claim: No
Assignee: Wyeth LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.